ribonucleotide reductase / DNA polymerase (dCTP competition) drugs for Non-Small Cell Lung Cancer
2 tracked ribonucleotide reductase / DNA polymerase (dCTP competition) drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the ribonucleotide reductase / DNA polymerase (dCTP competition) page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 41 Phase 2
Head-to-head evidence: Gemcitabine vs Gemcitabine (FF-10832)
The roster
← all ribonucleotide reductase / DNA polymerase (dCTP competition) drugs